Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Considerations in boosting COVID-19 vaccine immune responses
Philip R. Krause, Thomas R. Fleming, Richard Peto, et al.
The Lancet (2021) Vol. 398, Iss. 10308, pp. 1377-1380
Open Access | Times Cited: 352

Showing 1-25 of 352 citing articles:

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
Peter B. Gilbert, David C. Montefiori, Adrian B. McDermott, et al.
Science (2022) Vol. 375, Iss. 6576, pp. 43-50
Open Access | Times Cited: 1020
SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact
Marc Lipsitch, Florian Krammer, Gili Regev‐Yochay, et al.
Nature reviews. Immunology (2021) Vol. 22, Iss. 1, pp. 57-65
Open Access | Times Cited: 305
Covid-19 Vaccine Effectiveness in New York State
Eli S. Rosenberg, Vajeera Dorabawila, Delia Easton, et al.
New England Journal of Medicine (2021) Vol. 386, Iss. 2, pp. 116-127
Open Access | Times Cited: 300
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials
Gang Zeng, Qianhui Wu, Hongxing Pan, et al.
The Lancet Infectious Diseases (2021) Vol. 22, Iss. 4, pp. 483-495
Open Access | Times Cited: 267
SARS-CoV-2 vaccine protection and deaths among US veterans during 2021
Barbara A. Cohn, Piera M. Cirillo, Caitlin C. Murphy, et al.
Science (2021) Vol. 375, Iss. 6578, pp. 331-336
Open Access | Times Cited: 241
The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than good
Kevin Bardosh, Alexandre de Figueiredo, Rachel Gur‐Arie, et al.
BMJ Global Health (2022) Vol. 7, Iss. 5, pp. e008684-e008684
Open Access | Times Cited: 221
BNT162b2 Vaccine Booster and Mortality Due to Covid-19
Ronen Arbel, Ariel Hammerman, Ruslan Sergienko, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 26, pp. 2413-2420
Open Access | Times Cited: 217
Mutations on RBD of SARS-CoV-2 Omicron variant result in stronger binding to human ACE2 receptor
Cecylia S. Lupala, Yongjin Ye, Hong Chen, et al.
Biochemical and Biophysical Research Communications (2021) Vol. 590, pp. 34-41
Open Access | Times Cited: 209
COVID-19 vaccination: The road ahead
Daniel M. Altmann, Rosemary J. Boyton
Science (2022) Vol. 375, Iss. 6585, pp. 1127-1132
Closed Access | Times Cited: 180
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Annika Fendler, Elisabeth G.E. de Vries, Corine H. GeurtsvanKessel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 6, pp. 385-401
Open Access | Times Cited: 178
Review of COVID-19 testing and diagnostic methods
Olena Filchakova, Dina Dossym, Aisha Ilyas, et al.
Talanta (2022) Vol. 244, pp. 123409-123409
Open Access | Times Cited: 177
The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions
Valentina Carlini, Douglas M. Noonan, Eslam Abdalalem, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 157
Covid-19 vaccine hesitancy: Text mining, sentiment analysis and machine learning on COVID-19 vaccination Twitter dataset
Miftahul Qorib, Timothy Oladunni, Max Denis, et al.
Expert Systems with Applications (2022) Vol. 212, pp. 118715-118715
Open Access | Times Cited: 152
Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland
Piotr Rzymski, Barbara Poniedziałek, Andrzej Fal
Vaccines (2021) Vol. 9, Iss. 11, pp. 1286-1286
Open Access | Times Cited: 148
Temporal changes in factors associated with COVID-19 vaccine hesitancy and uptake among adults in Hong Kong: Serial cross-sectional surveys
Jingyi Xiao, Justin Cheung, Peng Wu, et al.
The Lancet Regional Health - Western Pacific (2022) Vol. 23, pp. 100441-100441
Open Access | Times Cited: 140
Assessing Acceptability of COVID-19 Vaccine Booster Dose among Adult Americans: A Cross-Sectional Study
Tesfaye Yadete, Kavita Batra, Dale Netski, et al.
Vaccines (2021) Vol. 9, Iss. 12, pp. 1424-1424
Open Access | Times Cited: 133
Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count
Andrea Antinori, Stefania Cicalini, Silvia Meschi, et al.
Clinical Infectious Diseases (2022) Vol. 75, Iss. 1, pp. e552-e563
Open Access | Times Cited: 110
SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine
Ryutaro Kotaki, Yu Adachi, Saya Moriyama, et al.
Science Immunology (2022) Vol. 7, Iss. 70
Open Access | Times Cited: 109
Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study
Massimo Fabiani, Maria Puopolo, Cristina Morciano, et al.
BMJ (2022), pp. e069052-e069052
Open Access | Times Cited: 98
SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic
Antonio Bertoletti, Nina Le Bert, Anthony T. Tan
Immunity (2022) Vol. 55, Iss. 10, pp. 1764-1778
Open Access | Times Cited: 92
Comparative Effectiveness of mRNA and Inactivated Whole-Virus Vaccines Against Coronavirus Disease 2019 Infection and Severe Disease in Singapore
M Premikha, Calvin J. Chiew, Wycliffe Enli Wei, et al.
Clinical Infectious Diseases (2022) Vol. 75, Iss. 8, pp. 1442-1445
Open Access | Times Cited: 73
A Global Picture: Therapeutic Perspectives for COVID-19
Vivek P. Chavda, Carron Kapadia, Shailvi Soni, et al.
Immunotherapy (2022) Vol. 14, Iss. 5, pp. 351-371
Open Access | Times Cited: 71
Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study
Jing Lian Suah, Masliyana Husin, Peter Seah Keng Tok, et al.
International Journal of Infectious Diseases (2022) Vol. 119, pp. 69-76
Open Access | Times Cited: 67
Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), the Netherlands, August to September 2021
Brechje de Gier, Stijn P. Andeweg, Jantien A. Backer, et al.
Eurosurveillance (2021) Vol. 26, Iss. 44
Open Access | Times Cited: 69
The emergence of new SARS-CoV-2 variant (Omicron) and increasing calls for COVID-19 vaccine boosters-The debate continues
Naushad Ahmad Khan, Hassan Al‐Thani, Ayman El‐Menyar
Travel Medicine and Infectious Disease (2021) Vol. 45, pp. 102246-102246
Open Access | Times Cited: 67
Page 1 - Next Page

Scroll to top